Case Studies

ICNAS
Academia: Optimize and validate research protocols with mAb drug aliquots
“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”

Ivanna Hrynchak
PhD Student, ICNAS, Universidade d Coimbra, Portugal

ExcellGene
Biosimilars: Reference Drug Aliquots for Faster Selection and Development of CHO-based Production Processes
“Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!”

Prof. (emeritus) Dr. Florian Wurm
Chief Scientific Officer and Founder, ExcellGene SA

UGA Biopharma GmbH
Aliquots: A New Solution to the Batch Variability Problem
“Evidentic drug aliquots have significantly reduced our development cycle time and strengthened our ability to do detailed [protein] characterization.”

Dr Stephan Schultz
Team Leader of Analytics/DSP at UGA Biopharma GmbH

Deka BioSciences
Reference Drug Aliquots: The right control for Assays
“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts.”

Pavel Khrimian
Co-founder & CBO at Deka Biosciences Inc